Changes in the plasma levels of cytokines/chemokines for predicting the response to chemoradiation therapy in rectal cancer patients

Tada,Noriko; Tsuno,Nelson   H.; Kawai,Kazushige; Murono,Koji; Nirei,Takako; Ishihara,Soichiro; Sunami,Eiji; Kitayama,Joji; Watanabe,Toshiaki

doi:10.3892/or.2013.2857

Changes in the plasma levels of cytokines/chemokines for predicting the response to chemoradiation therapy in rectal cancer patients

Authors:
- Noriko Tada
- Nelson H. Tsuno
- Kazushige Kawai
- Koji Murono
- Takako Nirei
- Soichiro Ishihara
- Eiji Sunami
- Joji Kitayama
- Toshiaki Watanabe
View Affiliations

Affiliations: Department of Surgical Oncology, University of Tokyo, Tokyo 113-0033, Japan
Published online on: November 19, 2013 https://doi.org/10.3892/or.2013.2857
Pages: 463-471

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, we aimed to characterize the predictive value of cytokines/chemokines in rectal cancer (RC) patients receiving chemoradiation therapy (CRT). Blood samples were obtained pre- and post-CRT from 35 patients with advanced RC, who received neoadjuvant CRT followed by surgery, and the correlation between plasma levels of cytokines/chemokines and the response to CRT was analyzed. The pre-CRT levels of soluble CD40-ligand (sCD40L) and the post-CRT levels of chemokine ligand-5 (CCL-5) were significantly associated with the depth of tumor invasion and with venous invasion. In addition, a significant decrease in sCD40L and CCL-5, as well as in platelet counts, was associated with a favorable response to CRT. A significant correlation between pre-CRT platelet counts and sCD40L was observed in patients with a favorable response. By contrast, higher post-CRT interleukin (IL)-6 was associated with a poor response. Platelets, immune system and cancer cells, cross-linked through various cytokines/chemokines, appear to play an important role in the response to CRT, and by understanding their roles, new approaches for the improvement of the therapy might be proposed.

View Figures

View References

1	Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Eng J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
2	Bosset JF, Collette L, Calais G, et al: Chemotherapy with preoperative radiotherapy in rectal cancer. N Eng J Med. 355:1114–1123. 2006. View Article : Google Scholar : PubMed/NCBI
3	Ortholan C, Francois E, Thomas O, et al: Role of radiotherapy with surgery for T3 and resectable T4 rectal cancer: evidence from randomized trials. Dis Colon Rectum. 49:302–310. 2006. View Article : Google Scholar : PubMed/NCBI
4	Debucquoy A, Goethals L, Geboes K, Roels S, Mc Bride WH and Haustermans K: Molecular responses of rectal cancer to preoperative chemoradiation. Radiother Oncol. 80:172–177. 2006. View Article : Google Scholar : PubMed/NCBI
5	Baier PK, Eggstein S, Wolff-Vorbeck G, Baumgartner U and Hopt UT: Chemokines in human colorectal carcinoma. Anticancer Res. 25:3581–3584. 2005.PubMed/NCBI
6	Dranoff G: Cytokines in cancer pathogenesis and cancer therapy (Review). Nat Rev Cancer. 4:11–22. 2004. View Article : Google Scholar
7	Okita R, Yamaguchi Y, Ohara M, et al: Targeting of CD4⁺CD25^high cells while preserving CD4⁺CD25^low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer. Int J Oncol. 34:563–572. 2009.
8	Ostrand-Rosenberg S: Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity (Review). Cancer Immunol Immunother. 59:1593–1600. 2010. View Article : Google Scholar : PubMed/NCBI
9	McDonnell AM, Nowak AK and Lake RA: Contribution of the immune system to the chemotherapeutic response. Semin Immunopathol. 33:353–367. 2011. View Article : Google Scholar : PubMed/NCBI
10	Ong ZY, Gibson RJ, Bowen JM, et al: Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol. 5:222010. View Article : Google Scholar : PubMed/NCBI
11	Schaue D, Kachikwu EL and McBride WH: Cytokines in radiobiological responses: a review (Review). Radiat Res. 178:505–523. 2012. View Article : Google Scholar : PubMed/NCBI
12	Lin WW and Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 117:1175–1183. 2007. View Article : Google Scholar : PubMed/NCBI
13	Lin CC, Liu CY, Chen MJ, et al: Profiles of circulating endothelial cells and serum cytokines during adjuvant chemoradiation in rectal cancer patients. Clin Transl Oncol. 15:855–860. 2013. View Article : Google Scholar : PubMed/NCBI
14	Chung YC and Chang YF: Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol. 83:222–226. 2003. View Article : Google Scholar : PubMed/NCBI
15	Waldner MJ, Foersch S and Neurath MF: Interleukin-6 - a key regulator of colorectal cancer development. Int J Biol Sci. 8:1248–1253. 2012. View Article : Google Scholar : PubMed/NCBI
16	Lopes CO and Callera F: Three-dimensional conformal radiotherapy in prostate cancer patients: rise in interleukin 6 (IL-6) but not IL-2, IL-4, IL-5, tumor necrosis factor-α, MIP-1-α, and LIF levels. Int J Radiat Oncol Biol Phys. 82:1385–1388. 2012.PubMed/NCBI
17	Andre P, Nannizzi-Alaimo L, Prasad SK and Phillips DR: Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 106:896–899. 2002. View Article : Google Scholar : PubMed/NCBI
18	Aukrust P, Damas JK and Solum NO: Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation? J Am Coll Cardiol. 43:2326–2328. 2004. View Article : Google Scholar : PubMed/NCBI
19	Schlom J, Jochems C, Gulley JL and Huang J: The role of soluble CD40L in immunosuppression. Oncoimmunology. 2:e225462013. View Article : Google Scholar : PubMed/NCBI
20	Huang J, Jochems C, Talaie T, et al: Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood. 120:3030–3038. 2012. View Article : Google Scholar : PubMed/NCBI
21	Schlecker E, Stojanovic A, Eisen C, et al: Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol. 189:5602–5611. 2012. View Article : Google Scholar
22	Umekawa K, Kimura T, Kudoh S, et al: Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs. BMC Res Notes. 6:1392013. View Article : Google Scholar : PubMed/NCBI
23	Lin S, Wan S, Sun L, et al: Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia. Cancer Sci. 103:904–912. 2012. View Article : Google Scholar : PubMed/NCBI
24	Chuang JY, Yang WH, Chen HT, et al: CCL5/CCR5 axis promotes the motility of human oral cancer cells. J Cell Physiol. 220:418–426. 2009. View Article : Google Scholar : PubMed/NCBI
25	Lapteva N and Huang XF: CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther. 10:725–733. 2010. View Article : Google Scholar : PubMed/NCBI
26	Zhang Y, Yao F, Yao X, et al: Role of CCL5 in invasion, proliferation and proportion of CD44⁺/CD24⁻ phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol Rep. 21:1113–1121. 2009.PubMed/NCBI
27	Yi EH, Lee CS, Lee JK, et al: STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells. Mol Cancer Res. 11:31–42. 2013. View Article : Google Scholar : PubMed/NCBI
28	Radziwon-Balicka A, Medina C, O'Driscoll L, et al: Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. Br J Pharmacol. 167:787–804. 2012. View Article : Google Scholar : PubMed/NCBI
29	Li R, Chen WC, Pang XQ, Hua C, Li L and Zhang XG: Expression of CD40 and CD40L in gastric cancer tissue and its clinical significance. Int J Mol Sci. 10:3900–3917. 2009. View Article : Google Scholar : PubMed/NCBI
30	Roselli M, Mineo TC, Basili S, et al: Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res. 10:610–614. 2004. View Article : Google Scholar : PubMed/NCBI
31	Pan W, Gong J, Yang C, et al: Peripheral blood CD40-CD40L expression in human breast cancer. Ir J Med Sci. Feb 28–2013.(Epub ahead of print).
32	Toutirais O, Gervais A, Cabillic F, et al: Effects of CD40 binding on ovarian carcinoma cell growth and cytokine production in vitro. Clin Exp Immunol. 149:372–377. 2007. View Article : Google Scholar : PubMed/NCBI
33	Li R, Chen WC, Pang XQ, Tian WY and Zhang XG: Influence of sCD40L on gastric cancer cell lines. Mol Biol Rep. 38:5459–5464. 2011. View Article : Google Scholar : PubMed/NCBI
34	Mathur RK, Awasthi A, Wadhone P, Ramanamurthy B and Saha B: Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat Med. 10:540–544. 2004. View Article : Google Scholar : PubMed/NCBI
35	Becker C, Fantini MC, Wirtz S, et al: IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle. 4:217–220. 2005. View Article : Google Scholar : PubMed/NCBI
36	Ardestani S, Li B, Deskins DL, Wu H, Massion PP and Young PP: Membrane versus soluble isoforms of TNF-α exert opposing effects on tumor growth and survival of tumor-associated myeloid cells. Cancer Res. 73:3938–3950. 2013.PubMed/NCBI
37	Ferroni P, Riondino S, Portarena I, et al: Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer. Int J Colorectal Dis. 27:1561–1567. 2012. View Article : Google Scholar
38	Kawai K, Kitayama J, Tsuno NH, Sunami E and Watanabe T: Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer. Int J Colorectal Dis. 28:527–535. 2013. View Article : Google Scholar